Secukinumab
What is Secukinumab Secukinumab is a subcutaneously administered human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine, inhibiting its interaction with the IL-17A receptor. Maintenance dosing is given once monthly. Secukinumab is useful in a variety of inflammatory disorders. Elevated concentrations of IL-17A are found in psoriatic plaques; secukinumab is approved for …